Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

The HeartWare™ HVAD™ Left Ventricular Assist Device 

The HeartWare™ HVAD™ Left Ventricular Assist Device
Chapter:
The HeartWare™ HVAD™ Left Ventricular Assist Device
Author(s):

Nicholas Hiivala

and Thomas Vassiliades

DOI:
10.1093/med/9780190909291.003.0013
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 17 January 2021

The HeartWareTM HVADTM System is an intrapericardial continuous-flow left-ventricular assist device with a centrifugal pump design capable of providing full cardiac support in patients with end-stage systolic heart failure. The inflow to the pump is inserted into the left ventricular apex and moves blood to the ascending aorta via a 10mm outflow graft and is most frequently implanted via a median sternotomy. The system is controlled by an external microprocessor unit that connects transcutaneously to the pump by way of a thin, flexible driveline and is powered by Li-ion batteries or AC/DC power. The HVAD was first implanted in man in 2006 and was subsequently approved for use in Europe in 2009 (CE Mark trial), for bridge to transplant in the United States in 2012 (ADVANCE trial), destination therapy in the United States in 2017 (ENDURANCE and ENDURANCE Supplemental trials), and implantation via a thoracotomy approach in the United States in 2018 (LATERAL trial).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.